Triple action eye drops launched for dry eye

Article

Allergan has announced the UK launch of the Optive Plus eye drops for treating severe dry eye symptoms in three different ways.

Allergan has announced the UK launch of the Optive Plus eye drops for treating severe dry eye symptoms in three different ways.

The treatment includes lipid-enhancing technology for the protection and stabilization of the lipid layer to help seal in moisture and reduce tear evaporation. Optive Plus features OsmoMax technology to moisturise and lubricate the eye surface. It also contains molecules that the company claims can penetrate deeper into the eye and hydrate corneal epithelial cells.

A recent study (Allergan data on file AG9965-001) involving 47 people suffering from dry eye demonstrated that the eye drops were safe and efficient in treating dry eye symptoms. Optive Plus showed a favourable tolerability profile.

Professor Alan Tomlinson, Department of Vision Sciences, Glasgow Caledonian University, said, “Dry eye can be a real problem for patients and in some cases can cause serious irritation, especially in patients suffering with moderate to severe dry eye symptoms. Optive Plus provides a clinically effective treatment that delivers relief from irritation, reduces tear evaporation and helps treat the underlying causes of dry eye, and will be a useful addition to the treatments we can offer to our patients.”

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.